Provided by Tiger Trade Technology Pte. Ltd.

iShares U.S. Pharmaceuticals ETF

98.65
-0.3500-0.35%
Post-market: 98.650.00000.00%19:30 EDT
Volume:663.75K
Turnover:65.34M
Market Cap:1.60B
PE:9.19
High:99.48
Open:99.33
Low:98.25
Close:99.00
52wk High:108.66
52wk Low:72.94
Shares:16.25M
Float Shares:16.25M
Volume Ratio:4.65
T/O Rate:4.08%
Dividend:1.44
Dividend Rate:1.46%
EPS(TTM):10.74
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

Sanofi’s Regeneron Fix Requires Extra Shot of M&A

Reuters
·
Oct 01

Bayer Names Christoph Koenen Chief Medical Officer

Reuters
·
Oct 01

Faron Pharmaceuticals Doses First Patient in Phase 1/2 BLAZE Trial of Bexmarilimab Plus Bristol Myers’ Opdivo in PD-1-Resistant Solid Tumors

Reuters
·
Oct 01

Merck & Co Inc : Jefferies Raises Target Price to $177 from $175

THOMSON REUTERS
·
Oct 01

RBC Capital Keeps Their Hold Rating on Merck & Company (MRK)

TIPRANKS
·
Oct 01

The Next Frontier for Obesity Drugs Isn't How Much Weight You Lose, but What Kind

Dow Jones
·
Oct 01

Eli Lilly Says Foundayo Drug Helped Patients Lose Weight in Phase 3 Trial

Dow Jones
·
Oct 01

Eli Lilly’s Foundayo shows cardiovascular safety in type 2 diabetes study

TIPRANKS
·
Oct 01

Lilly's Oral Glp-1, Foundayo (Orforglipron), Demonstrated Cardiovascular Safety Alongside Sustained A1c Reduction and Weight Loss in Its Largest and Longest Type 2 Diabetes Study

THOMSON REUTERS
·
Oct 01

Eli Lilly - Achieve-4: Foundayo Shows 16% Lower Mace-4 and 23% Lower Mace-3 Risk vs Insulin Glargine

THOMSON REUTERS
·
Oct 01

Eli Lilly - Foundayo Shows Smaller Egrf Reduction and Greater Albuminuria Reduction vs Insulin Glargine

THOMSON REUTERS
·
Oct 01

U.S. Food and Drug Administration Approves Expanded Indication for Bristol Myers Squibb’s Camzyos® (Mavacamten) for the Treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy (Ohcm) in Adults and Pediatric Patients*

THOMSON REUTERS
·
Oct 01

Estee Lauder Cos. Cl a Stock Underperforms Wednesday When Compared to Competitors

Dow Jones
·
Oct 01

Abbott Laboratories Stock Underperforms Wednesday When Compared to Competitors

Dow Jones
·
Oct 01

Royalty Pharma EVP Research & Investments Marshall Urist Sells 4,126 Shares for $238,812.88

Reuters
·
Oct 01

Merck, 3M Share Losses Contribute to Dow's 286-Point Drop

Dow Jones
·
Oct 01

Bristol-Myers Squibb's Camzyos to Treat Heart Condition Receives FDA Approval for Pediatric Patients

MT Newswires Live
·
Oct 01

FDA: Approved Camzyos (Mavacamten) Capsules as First Treatment for Children with Symptomatic Obstructive Hypertrophic Cardiomyopathy - Website

THOMSON REUTERS
·
Oct 01

FDA Approves First Drug to Improve Functional Capacity and Symptoms in Children with Rare Inherited Heart Condition

THOMSON REUTERS
·
Oct 01

FDA: Camzyos Carries Boxed Warning for Heart Failure Risk, Restricted to Rems Program

THOMSON REUTERS
·
Oct 01